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Effects of age on the risk of dying from pulmonary
embolism or bleeding during treatment of deep
vein thrombosis
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Background: The risk of patients dying of pulmonary embolism (PE) or bleeding during the treatment of deep vein
thrombosis (DVT), and whether these risks are influenced by patient age, has not been thoroughly studied.
Methods: We used data from the Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) to assess the risk
of fatal PE and fatal bleeding in 16,199 patients with lower limb DVT (without symptomatic PE at the time of inclusion)
during the 3 months after diagnosis, with patients categorized according to age.
Results: During the 3 months of anticoagulant treatment, there were 31 fatal PEs (0.19%) and 83 fatal hemorrhages
(0.51%). During the first 7 days of therapy, the frequency of fatal PEs was similar to that of fatal bleeding (12 vs 14
deaths, respectively; odds ratio [OR], 0.86; 95% confidence interval [CI], 0.39-1.87). However, from days 8 to 90, the
frequency of fatal bleeding was greater than that of fatal PE (69 vs 19 deaths; OR, 3.64; 95% CI, 2.22-6.20). The higher
frequency of fatal bleeding compared with fatal PE from days 8 to 90 appeared to be confined to patients who were aged
>60 years. Multivariate analysis showed that patient age was independently associated with an increased risk of death
from bleeding during the first 3 months: every 10 years the OR increased by 1.37 (95% CI, 1.12-1.67).
Conclusions: During the first week of treatment, the risk of fatal bleeding and fatal PE were similar. Then, particularly in
patients who were aged >60 years, the risk of dying from bleeding exceeded the risk of dying from PE. (J Vasc Surg
2011;54:26S-32S.)
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oThe main objectives of anticoagulant therapy in the
initial treatment of deep vein thrombosis (DVT) are to
prevent thrombus extension and pulmonary embolism
(PE). Current guidelines from the American College of
Chest Physicians recommend that patients with acute DVT
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26Se treated initially with unfractionated heparin (UFH),
ow-molecular-weight heparin (LMWH), or fondaparinux,
ollowed by long-term treatment, usually with vitamin K
ntagonists (VKA).1 The need for long-term therapy for
VT and the preferred intensity of the anticoagulant effect
f VKA therapy have been established by randomized clin-
cal trials.2-6 However, elderly patients are often excluded
rom clinical trials of anticoagulant therapy because of
omorbid conditions, short life expectancy, long-term im-
obility, or contraindications to therapy, which means that
reatment regimens derived from the results from clinical
rials might not be optimal for elderly patients with DVT.
urthermore, an increasing body of evidence supports age
s an independent risk factor for major bleeding on antico-
gulant treatment.7,8
The Registro Informatizado de la Enfermedad Trom-
oEmbólica (RIETE) registry is an ongoing, international
Spain, France, Italy, Israel, Germany, Switzerland, Repub-
ic of Macedonia and Brazil), multicenter, prospective reg-
stry of consecutive patients presenting with symptomatic
cute venous thromboembolism (VTE). Data from RIETE
ave been used to evaluate outcomes after acute VTE, such
s the frequency of recurrent VTE, bleeding, and death,
long with the risk factors for these outcomes.9-11 We have
reviously reported the frequency of recurrent VTE and
ajor bleeding in the elderly and risk factors for these two
utcomes in the 3 months after diagnosis of acute
TE.12,13 The current analysis focuses on the frequency of
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Volume 54, Number 19S Sanchez Muñoz-Torrero et al 27Sand risk factors for fatal PE and fatal bleeding developing
during the first 3 months after acute DVT of the lower
limbs. We were especially interested in determining if age
influences a patient’s risk of dying of bleeding or PE during
treatment.
PATIENTS AND METHODS
Consecutive patients with symptomatic, acute lower
limb DVT, confirmed by compression ultrasound imaging
or contrast venography, were enrolled in RIETE. Patients
were excluded if they did not receive any anticoagulant
therapy or were currently participating in a therapeutic
clinical trial with a blinded therapy. All patients provided
written or oral consent for participation in the registry, in
accordance with local ethics committee requirements.
Physicians participating in the RIETE registry ensured
that eligible patients were consecutively enrolled. Data
were recorded in a computer-based case report form at each
participating hospital and submitted to a centralized coor-
dinating center through a secure Web site. The study
Coordinating Center assigned patients with a unique iden-
tification number to maintain patient confidentiality and
was responsible for all data management. Data quality was
regularly monitored electronically, including checks to de-
Table I. Clinical characteristics of 16,199 patients with lo
Variable a
Age
29 30-39 40-49 5
Patients, N 750 1185 1448
Clinical characteristics
Male sex 298 (40) 601 (51) 852 (59) 122
Body weight 72  17 78  17 79  17 79
Comorbidity
Chronic heart
failure 1 (0.1) 1 (0.1) 9 (1.7) 3
Chronic lung
disease 8 (1.1) 15 (1.3) 46 (3.2) 11
Abnormal
creatinine level 7 (1.0) 33 (2.9) 72 (5.1) 11
Recent major
bleeding 6 (0.8) 18 (1.5) 35 (2.4) 3
Risk factors for DVT
Cancer 19 (2.5) 65 (5.5) 210 (15) 43
Postoperative 85 (11) 150 (13) 170 (12) 23
Immobility 4
days 171 (23) 268 (23) 321 (22) 42
Recent travel 32 (4.4) 51 (4.4) 63 (4.5) 8
Estrogen use 261 (35) 209 (18) 109 (7.7) 3
Pregnancy/
puerperium 66 (13) 95 (13) 10 (1.2)
Idiopathicc 220 (29) 482 (41) 693 (48) 87
Prior VTE 69 (9.2) 184 (16) 241 (17) 36
DVT characteristics
Proximal (vs distal) 597 (80) 923 (78) 1089 (75) 144
Bilateral (vs
unilateral) 22 (2.9) 38 (3.2) 44 (3.0) 8
aContinuous data are shown as mean  standard deviation; categoric data a
bThe P value is for trend with increasing decades of age. P  .05 is significa
cNone of the above.tect inconsistencies or errors, which were resolved by con-acting the local coordinators. Data quality was also moni-
ored by periodic visits to participating hospitals by contract
esearch organizations that compared medical records with
he submitted data.
Study outcomes. The major outcome for this study
as the development of fatal PE or fatal bleeding within the
rst 90 days of diagnosis of acute DVT. Fatal PE, in the
bsence of autopsy confirmation, was defined as any death
ppearing 10 days of PE diagnosis, in the absence of any
lternative cause of death. Fatal bleeding was defined as any
eath occurring 10 days of a major bleeding episode in
he absence of an alternative cause of death. Major bleeding
as defined as an overt hemorrhage that required a trans-
usion of 2 units of blood, was retroperitoneal, spinal or
ntracranial, or was fatal.
Baseline variables. The following patient parameters
ere recorded when the qualifying episode of DVT was
iagnosed:
● sex, age, and body weight;
● presence of coexisting conditions such as chronic heart
or lung disease;
● recent (30 days before VTE) major bleeding;
● presence of risk factors for DVT, including active
imb deep vein thrombosis (DVT), according to age
ars
Total P b60-69 70-79 79
3050 4579 3295 16,199
5) 1803 (59) 2400 (52) 1209 (37) 8390 (52) .001
5 77  14 74  12 67  12 74  15 .001
.7) 77 (2.5) 213 (4.7) 320 (9.7) 653 (4.0) .001
.8) 274 (9.0) 541 (12) 320 (9.7) 1314 (8.1) .001
.2) 329 (11) 710 (16) 807 (25) 2073 (13) .001
.0) 54 (1.8) 111 (2.4) 71 (2.2) 332 (2.0) .041
3) 786 (26) 1103 (24) 650 (20) 3268 (20) .001
3) 340 (11) 496 (11) 220 (6.7) 1697 (11) .001
2) 650 (21) 1155 (25) 1213 (37) 4202 (26) .001
.5) 79 (2.7) 52 (1.2) 14 (0.4) 374 (2.4) .001
.9) 29 (1.0) 26 (0.6) 16 (0.5) 686 (4.3) .001
0 0 0 171 (1.1) .001
6) 1486 (49) 2180 (47) 1453 (44) 7391 (46) .001
9) 533 (18) 829 (18) 515 (16) 2732 (17) .001
6) 2432 (80) 3774 (82) 2879 (87) 13,138 (81) .001
.5) 91 (3.0) 123 (2.7) 111 (3.4) 515 (3.2) .013
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December Supplement 201128S Sanchez Muñoz-Torrero et althat was being treated by surgery, chemotherapy, ra-
diotherapy, hormonal, support therapy, or combined
treatments), recent immobilization (defined as non-
surgical patients who were confined to bed with bath-
room privileges for 4 days in the 2 months before
VTE diagnosis), and surgery (defined as those who had
undergone an operation in the 2 months before VTE);
● extent of the DVT (distal DVT was DVT confined to
the infrapopliteal veins); and
● laboratory data, including serum creatinine levels on
admission and international normalized ratio (INR)
levels during follow-up in patients receiving VKA
treatment.
Treatment and follow-up. Treatment was not stan-
dardized, and patients were managed according to the
clinical practice of each participating hospital. The type,
dose, and duration of anticoagulant therapy was recorded.
Patients were monitored for up to 3 months in the outpa-
tient clinic. During each visit, any signs or symptoms sug-
gesting DVT or PE recurrences or bleeding complications
Table II. Treatment strategies and 90-day outcome accor
Variables a
Age
29 30-39 40-49 5
Patients, N 750 1185 1448 1
Initial therapy
LMWH 710 (95) 1113 (94) 1370 (95) 182
LMWH dose
(IU/kg/d) 181  37 176  37 174  39 173
UFH 26 (3.5) 49 (4.1) 52 (3.6) 4
Fondaparinux 9 (1.2) 15 (1.3) 18 (1.2) 2
Thrombolytics 1 (0.1) 1 (0.1) 1 (0.1)
Other 3 (0.4) 6 (0.5) 6 (0.4)
IVC filter 13 (1.7) 17 (1.4) 28 (1.9) 4
Long-term
therapy
Antivitamin K 589 (79) 867 (73) 1077 (75) 133
INR 2.19 0.73 2.32 0.60 2.28 0.71 2.39
LMWH 150 (20) 300 (25) 334 (23) 51
LMWH dose
(IU/kg/d) 151  51 146  52 141  48 141
90-day outcome
Recurrent DVT 12 (1.6) 19 (1.6) 15 (1.0) 2
Recurrent PE 7 (0.9) 10 (0.8) 12 (0.8) 1
Recurrent VTE 19 (2.5) 29 (2.4) 27 (1.9) 4
Major bleeding 4 (0.5) 7 (0.6) 10 (0.7) 2
Overall death 0 14 (1.2) 45 (3.1) 9
Fatal PE
All 0 0 4 (0.3)
Day 0-7 0 0 1 (0.1)
Day 8-90 0 0 3 (0.2)
Fatal bleeding
All 0 0 1 (0.1)
Day 0-7 0 0 0
Day 8-90 0 0 1 (0.1)
DVT, Deep vein thrombosis; IVC, inferior vena cava; LMWH, low-molecula
venous thromboembolism.
aContinuous data are shown as mean  standard deviation; categoric data a
bThe P value is for trend with increasing decades of age; P  .05 is significawere noted. Each episode of clinically suspected recurrent wVT or PE was investigated by repeat ultrasound imaging,
enography, lung scanning, helical computed tomography
CT) scan, or pulmonary angiography, as appropriate.
Most outcomes were classified as reported by the clin-
cal centers. If staff at the coordinating center were uncer-
ain how to classify a reported outcome, a central adjudi-
ating committee reviewed that event (10% of events).
atients who had major bleeding or recurrent VTE 3
onths of enrollment remained under surveillance until 3
onths of follow-up was completed.
Statistical analysis. The influence of age was assessed
y comparing across decades (P values are reported for
rends). The Student t test and the Mann-Whitney test
ere used to compare continuous variables. Categoric vari-
bles were compared by the Fisher exact test. The odds
atio (OR) and 95% confidence intervals (CIs) were calcu-
ated, and adjusted ORs were calculated by controlling for
elevant covariates by means of multiple logistic regression
nalysis. Covariates entered in the models were selected by
significance level of P  .20 in univariate analysis, or by a
to age
rs
Total P b60-69 70-79 79
3050 4579 3295 16,199
) 2929 (96) 4416 (97) 3162 (96) 15,523 (96)
174  37 175  38 177  40 175  39 .001
) 69 (2.3) 114 (2.5) 86 (2.6) 438 (2.7) .003
) 33 (1.1) 30 (0.7) 19 (0.6) 144 (0.9) .041
2 (0.1) 3 (0.1) 1 (0.0) 9 (0.1) .856
) 13 (0.4) 10 (0.2) 21 (0.6) 65 (0.4) .165
) 65 (2.1) 95 (2.1) 43 (1.3) 306 (1.9) .068
) 2187 (73) 3235 (72) 1947 (61) 11,235 (71) .001
1 2.38 0.64 2.35 0.80 2.49 0.66 2.36 0.71 .256
) 793 (26) 1213 (27) 1211 (38) 4512 (28) .001
137  48 138  49 144  50 141  49 .001
) 46 (1.5) 59 (1.3) 21 (0.6) 201 (1.2) .017
) 27 (0.9) 19 (0.4) 23 (0.7) 111 (0.7) .219
) 73 (2.4) 78 (1.7) 44 (1.3) 312 (1.9) .021
) 60 (2.0) 74 (1.6) 105 (3.2) 284 (1.8) .001
) 180 (5.9) 272 (5.9) 351 (11) 961 (5.9) .001
) 5 (0.2) 7 (0.2) 12 (0.4) 31 (0.2) .125
1 (0.0) 5 (0.1) 5 (0.2) 12 (0.1) .322
) 4 (0.1) 2 (0.0) 7 (0.2) 19 (0.1) .220
) 24 (0.8) 21 (0.5) 32 (1.0) 83 (0.5) .001
) 2 (0.1) 4 (0.1) 7 (0.2) 14 (0.1) .153
) 22 (0.7) 17 (0.4) 25 (0.8) 69 (0.4) .001
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Volume 54, Number 19S Sanchez Muñoz-Torrero et al 29SThe treatment received by the patients was not in-
cluded in the univariate or multivariate models because
choice of treatment was expected to have been influenced
by the physician’s assessment of a patient’s risk of bleeding
and recurrent VTE. Variables obtained during follow-up
and that were not available at baseline were not included as
potential predictors of bleeding. The Kaplan-Meier
method was used to create survival curves. SPSS 15 soft-
ware (SPSS Inc, Chicago, Ill) was used for the statistical
management of the data. A two-sided P  .05 was consid-
ered to be statistically significant.
RESULTS
As of September 2010, 32,980 patients had been en-
rolled in RIETE, of which 16,199 (49%) presented with
DVT in the lower limbs without symptoms suggesting PE
and were included in the current analysis. Their clinical
characteristics are reported in Table I. The prevalence of
chronic heart failure, chronic lung disease, abnormal creat-
inine levels, cancer, or immobility 4 days increased with
increasing age. The proportion of patients with proximal
DVT also increased with advancing age.
LMWH was the initial therapy in 96% of patients, with
no differences in mean daily doses according to age (Table
II). Then, most received VKA rather than LMWH as
long-term therapy, but a lower proportion of patients aged
79 years received LMWH as long-term therapy compared
with younger patients. There were no differences in the
mean INR results according to age. The incidence of
0,000
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Fig. Cumulative incidence is shown of fatal bleedrecurrent VTE during the 3-month period decreased with odvancing age, whereas the incidence of major bleeding
ncreased (Table II).
During the 3 months of follow-up, while receiving
nticoagulant therapy, 111 patients (0.7%) were diagnosed
ith symptomatic PE, 284 (1.7%) had major bleeding
vents, and 961 (5.9%) died. Of the 111 patients with PE,
1 (28%) died of the PE event, and bleeding was fatal in 83
f 284 patients (29%) with major bleeding (Table II). The
elative frequency of fatal PE and fatal bleeding differed
ccording to the period of follow-up: during the first 7 days
f therapy, the incidence of fatal PE was similar to that of
atal bleeding (12 vs 14 deaths, respectively; OR, 0.9; 95%
I, 0.4-1.9), but from day 8, the incidence of fatal bleeding
as more than threefold greater than that of fatal PE (69 vs
9 deaths; OR, 3.6; 95% CI, 2.2-6.2; Fig, Table II). The
elative frequency of fatal PE and fatal bleeding from days 8
o 90 appeared to differ according to patient age: there
ere five fatal hemorrhages and six fatal PEs in patients
ged 60 years but 64 fatal hemorrhages and 13 fatal PEs
n patients aged 60 years (Table II).
Univariate analysis found that age, inpatient status,
hronic lung disease, recent major bleeding, cancer, and
mmobility 4 days were all associated with an increased
ncidence of fatal PE and that patients with idiopathic DVT
ad a lower incidence of fatal PE (Table III). In univariate
nalysis, age, body weight 70 kg, in-patient status,
hronic heart failure, recent major bleeding, abnormal cre-
tinine levels, proximal DVT, bilateral DVT, cancer, and
mmobility4 days were associated with a higher incidence
5 48 51 54 57 60 63 66 69 72 75 78 81 84 87 90
ays
nd fatal pulmonary embolism (PE)  3 months.42 4
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fatal bleeding. Multivariate analysis showed the patient’s
age was not associated with an increased risk of death from
recurrent PE but was independently associated with an
increased risk of death from bleeding during the first 3
months: for every 10 years the OR increased by 1.4 (95%
CI, 1.1-1.7), starting at age 29 years (Table IV).
DISCUSSION
This analysis found that the risk of fatal bleeding was
more than twice as high as the risk of fatal PE during 3
months of treatment for acute DVT. During the first week
of treatment, the risk of both fatal bleeding and fatal PE
were high and similar. After the first week of treatment, the
risk of fatal PE decreased markedly, whereas the risk of fatal
bleeding remained high until the end of the first month of
treatment. After the first month of treatment, the risk of
fatal bleeding decreased to a similar level as the risk of fatal
PE.
Patient age influenced the risk of having a fatal hemor-
rhage and a fatal PE as well as the relative frequency of these
two outcomes. In patients aged 60 years, the risk of fatal
Table III. Univariate analysis of the risk to develop fatal p
Variable a
Fatal P
Yes
Patients, N 31
Male sex 15 (48)
Age, years 71  16b
Weight 70 kg 14 (45)
In-patient at diagnosis 15 (48)b
Comorbidities
Chronic heart failure 1 (3.2)
Chronic lung disease 6 (19)b
Recent major bleeding 3 (9.7)d
Abnormal creatinine levels 6 (19)
Location of the DVT
Proximal (vs distal) 26 (84)
Bilateral (vs unilateral) 2 (6.5)
Risk factors
Cancer 15 (48)c
Postoperative 4 (13)
Immobility 4 days 14 (45)b
Recent travel 1 (3.2)
Estrogen use 0
Pregnancy/puerperium 0
Idiopathice 5 (16)d
Prior VTE 4 (13)
Initial therapy
LMWH 27 (87)b
UFH 2 (6.5)
Other 2 (6.5)c
Inferior vena cava filter 1 (3.2)
Long-term therapy
Vitamin K antagonists 6 (29)c
LMWH 14 (67)c
DVT, Deep vein thrombosis; LMWH, low-molecular-weight heparin; UFH
aCategoric variables are shown as mean  standard deviation; continuous v
Comparisons between patients with vs without the event: bP .05; cP  .0
eNone of the above.bleeding was 0.13%, and the risk of fatal PE was 0.11% turing 3 months of treatment; the relative risk of fatal
leeding vs a fatal PE was the same during the first week of
reatment (0.02% vs 0.02%) and subsequently (0.11% vs
.09%). In patients aged 60 years, the risk of fatal bleed-
ng was 0.70%, and the risk of fatal PE was 0.22% during 3
onths of treatment. Although the relative risk of having a
atal hemorrhage vs a fatal PE was the same during the first
eek of treatment (0.12% vs 0.10%), fatal bleeding was
uch more frequent than fatal PE subsequently (0.59% vs
.12%).
Differences in the intensity of long-term anticoagula-
ion did not appear to account for the difference in out-
omes in those aged younger and older than 60 years
ecause INR results and LMWH doses did not differ
ystematically with age. During the 3 months of treatment,
he higher frequency of fatal bleeding in patients aged60
ears compared to those who were aged60 years was due
o both a higher frequency of bleeding episodes (2.2% vs
.9%) and a higher probability of dying (ie, case-fatality)
hen bleeding occurred (32% vs 13%).
The similar risk of dying from bleeding and PE during
nary embolism (PE) or fatal bleeding within 3 months
Fatal bleeding
No Yes No
16,168 83 16,116
8375 (52) 42 (51) 8348 (52)
65  18b 75  11c 65  18
5669 (37) 49 (59)c 5934 (37)
4379 (28) 33 (40)b 4361 (28)
652 (4.0) 8 (9.6)d 645 (4.0)
1308 (8.1) 6 (7.2) 1308 (8.1)
329 (2.0) 9 (11)b 323 (2.0)
2067 (13) 34 (41)c 2039 (13)
3,112 (81) 77 (93)d 13,061 (81)
513 (3.2) 11 (13)c 504 (3.1)
3253 (20) 46 (55)c 3222 (20)
1693 (11) 4 (4.8)c 1693 (11)
4188 (26) 46 (55)c 4156 (26)
373 (2.4) 0 374 (2.4)
686 (4.3) 0 686 (4.3)
171 (3.2) 0 171 (3.2)
7386 (46) 15 (18)c 7376 (46)
2728 (17) 5 (6.0)d 2727 (17)
5,496 (96) 78 (94) 15,445 (96)
436 (2.7) 4 (4.8) 434 (2.7)
63 (0.4) 0 65 (0.4)
305 (1.9) 7 (8.4)c 299 (1.9)
1,229 (71) 21 (42)c 11,214 (71)
4498 (28) 29 (58)c 4483 (28)
ctionated heparin; VTE, venous thromboembolism.
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outcome of fatal bleeding and fatal PE during this period.
The much higher risk of dying of bleeding from PE after
the first week of therapy suggests that a less aggressive
anticoagulant strategy might reduce fatal bleeding more
than it would increase fatal PE during this period. In
addition to the increased risk for fatal bleeding in patients
aged70 years, there is also a lower risk of recurrent DVT
and PE compared with patients aged 70 years.
Because the risk of dying of bleeding was higher in
older patients, older patients might have the potential to
gain more if less aggressive anticoagulation reduces fatal
bleeding more than it increases fatal PE. However, ran-
domized trials would need to establish that less aggressive
anticoagulant therapy is superior to standard anticoagulant
therapy before the former could be recommended. Con-
trary to expectation, lowering the intensity of VKA therapy
from a target INR of 2.5 to 1.75 after the first 3 months of
treatment did not reduce bleeding but increased recurrent
VTE in patients with unprovoked VTE in the Extended
Low-Intensity Anticoagulation for Thromboembolism
study.5
The incidence of fatal PE of 0.19% that we observed
during the 3-month period is similar to that reported in
several randomized clinical trials, but the incidence of fatal
bleeding of 0.51% was more than twofold higher than has
been reported in such trials.14-17 We suspect that the higher
incidence of fatal bleeding in the current analysis reflects
Table IV. Multivariate analysis on the risk of developing
fatal pulmonary embolism (PE) or fatal bleeding within 3
months
Variable
Fatal PE Fatal bleeding
OR (95% CI) OR (95% CI)
Clinical characteristics
Male sex 0.8 (0.4-1.7) 1.3 (0.8-2.0)
Age (every 10 years) 1.1 (0.9-1.5) 1.4 (1.1-1.7)a
Body weight 70 kg 1.1 (0.5-2.3) 1.7 (1.1-2.8)a
In-patient 2.0 (0.99-4.2) 1.3 (0.8-2.0)
Comorbidity
Chronic heart disease 0.5 (0.1-4.1) 1.0 (0.4-2.4)
Chronic lung disease 2.5 (1.0-6.3)a 0.7 (0.3-1.6)
Recent major bleeding 2.8 (0.8-9.7) 3.4 (1.7-7.1)b
Abnormal creatinine levels 1.2 (0.5-3.0) 2.7 (1.7-4.3)c
Location of the DVT
Proximal vs distal 1.0 (0.4-2.8) 2.1 (0.9-4.9)
Bilateral vs unilateral 1.4 (0.3-5.8) 3.1 (1.6-6.0)b
Risk factors
Cancer 2.9 (1.1-7.5)a 5.8 (3.1-10)c
Postoperative 0.9 (0.3-3.1) 0.4 (0.1-1.2)
Immobility 4 days 1.7 (0.6-4.6) 3.3 (1.8-5.9)c
Recent travel 2.3 (0.3-20) 0
Idiopathicd 0.6 (0.1-2.3) 1.6 (0.7-4.0)
Prior VTE 0.8 (0.3-2.4) 0.3 (0.1-0.8)a
CI, Confidence interval; DVT, deep vein thrombosis; OR, odds ratio; VTE,
venous thromboembolism.
aP  .05; bP  .01; cP  .001.
dNone of the above.enrollment of consecutive unselected patients, including Core older patients and patients with multiple risk factors
or bleeding, who are often excluded from randomized
rials.
The present study has several limitations: First, patients
ere not treated with a standardized anticoagulant regi-
en. Treatment varied with local practice and was likely
nfluenced by the physician’s assessment of a patient’s risk
f bleeding.
Second, data were not enough to enable us to assess the
nfluence on fatal bleeding of INR control and type of VKA
sed.
Third, the apparent difference in the relative frequency
f fatal bleeding and fatal PE according to the age of
atients could have been a chance finding and requires
alidation in an independent population.
Fourth, to fulfill the definition of fatal PE in RIETE,
atients must first experience an objectively confirmed re-
urrent PE, followed by death 10 days. All sudden unex-
lained deaths, which are usually considered as “likely” fatal
ecurrent PE, are not considered in this analysis. The rate of
atal PE may therefore be underestimated, especially after
ospital discharge.
Finally, because we studied only the initial 3 months of
reatment, the findings of this analysis may not apply to the
ccurrence of fatal PE and fatal bleeding during more
rolonged anticoagulant therapy.
Among the strengths of the current analysis are that a
arge number of consecutive unselected patients were en-
olled, and that fatal PE and fatal bleeding are by far the
ost important outcomes during the treatment of acute
VT. In addition, when considering the trade-off between
ncreases in bleeding and decreases in recurrent VTE with
ifferent approaches to management, fatal PE and fatal
leeding are of equal importance; however, that is not the
ase when nonfatal episodes of recurrent VTE and bleed-
ng, such as a recurrent DVT and a nonfatal intracranial
leed, are included.
ONCLUSIONS
Age is significantly associated with the risk of fatal PE
nd fatal bleeding in patients with DVT, and after the first
eek of treatment, the risk of fatal bleeding exceeds the risk
f fatal PE. This suggests that less aggressive anticoagulant
herapy might be indicated after the first week of treatment,
articularly in elderly patients. This hypothesis, however,
hould be assessed in prospective clinical trials.
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